Cargando…

p-mTOR, p-ERK and PTEN Expression in Tumor Biopsies and Organoids as Predictive Biomarkers for Patients with HPV Negative Head and Neck Cancer

BACKGROUND: Survival rates of head and neck squamous cell carcinoma (HNSCC) have only marginally improved in the last decades. Hence there is a need for predictive biomarkers for long-time survival that can help to guide treatment decisions and might lead to the development of new therapies. The pho...

Descripción completa

Detalles Bibliográficos
Autores principales: de Kort, W. W. B., de Ruiter, E. J., Haakma, W. E., Driehuis, E., Devriese, L. A., van Es, R. J. J., Willems, S. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514008/
https://www.ncbi.nlm.nih.gov/pubmed/37486536
http://dx.doi.org/10.1007/s12105-023-01576-4
_version_ 1785108635184005120
author de Kort, W. W. B.
de Ruiter, E. J.
Haakma, W. E.
Driehuis, E.
Devriese, L. A.
van Es, R. J. J.
Willems, S. M.
author_facet de Kort, W. W. B.
de Ruiter, E. J.
Haakma, W. E.
Driehuis, E.
Devriese, L. A.
van Es, R. J. J.
Willems, S. M.
author_sort de Kort, W. W. B.
collection PubMed
description BACKGROUND: Survival rates of head and neck squamous cell carcinoma (HNSCC) have only marginally improved in the last decades. Hence there is a need for predictive biomarkers for long-time survival that can help to guide treatment decisions and might lead to the development of new therapies. The phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR signaling pathway is the most frequently altered pathway in HNSCC, genes are often mutated, amplificated and overexpressed causing aberrant signaling affecting cell growth and differentiation. Numerous genetic alterations of upstream and downstream factors have currently been clarified. However, their predictive value has yet to be established. Therefore we assess the predictive value of p-mTOR, p-ERK and PTEN expression. METHODS: Tissue microarrays (TMA’s) of HPV-negative patients with oropharyngeal (n = 48), hypopharyngeal (n = 16) or laryngeal (n = 13) SCC, treated with primary chemoradiation (cisplatin/carboplatin/cetuximab and radiotherapy), were histologically stained for p-mTOR, PTEN and p-ERK. Expression was correlated to overall survival (OS), disease free survival (DFS) and locoregional control (LRC). Also p-mTOR was histologically stained in a separate cohort of HNSCC organoids (n = 8) and correlated to mTOR-inhibitor everolimus response. RESULTS: High p-mTOR expression correlated significantly with worse OS in multivariate analysis in the whole patient cohort [Hazar Ratio (HR) 1.06, 95%CI 1.01–1.11, p = 0.03] and in the cisplatin/carboplatin group with both worse OS (HR 1.09, 95%CI 1.02–1.16, p = 0.02) and DFS (HR 1.06, 95%CI 1.00–1.12, p = 0,04). p-ERK expression correlated significantly with DFS in univariate analysis in the whole patient cohort (HR 1.03, 95%CI 1.00–1.05, p = 0.04) and cisplatin/carboplatin group (HR 1.03, 95%CI 1.00–1.07, p = 0.04). PTEN-expression did not correlate with OS/DFS/LRC. Better organoid response to everolimus correlated significantly to higher p-mTOR expression (Rs = − 0.731, p = 0.04). CONCLUSIONS: High p-mTOR expression predicts and high p-ERK expression tends to predict worse treatment outcome in HPV negative HNSCC patients treated with chemoradiation, providing additional evidence that these markers are candidate prognostic biomarkers for survival in this patient population. Also this study shows that the use of HNSCC organoids for biomarker research has potential. The role of PTEN expression as prognostic biomarker remains unclear, as consistent evidence on its prognostic and predictive value is lacking. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12105-023-01576-4.
format Online
Article
Text
id pubmed-10514008
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-105140082023-09-23 p-mTOR, p-ERK and PTEN Expression in Tumor Biopsies and Organoids as Predictive Biomarkers for Patients with HPV Negative Head and Neck Cancer de Kort, W. W. B. de Ruiter, E. J. Haakma, W. E. Driehuis, E. Devriese, L. A. van Es, R. J. J. Willems, S. M. Head Neck Pathol Research BACKGROUND: Survival rates of head and neck squamous cell carcinoma (HNSCC) have only marginally improved in the last decades. Hence there is a need for predictive biomarkers for long-time survival that can help to guide treatment decisions and might lead to the development of new therapies. The phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR signaling pathway is the most frequently altered pathway in HNSCC, genes are often mutated, amplificated and overexpressed causing aberrant signaling affecting cell growth and differentiation. Numerous genetic alterations of upstream and downstream factors have currently been clarified. However, their predictive value has yet to be established. Therefore we assess the predictive value of p-mTOR, p-ERK and PTEN expression. METHODS: Tissue microarrays (TMA’s) of HPV-negative patients with oropharyngeal (n = 48), hypopharyngeal (n = 16) or laryngeal (n = 13) SCC, treated with primary chemoradiation (cisplatin/carboplatin/cetuximab and radiotherapy), were histologically stained for p-mTOR, PTEN and p-ERK. Expression was correlated to overall survival (OS), disease free survival (DFS) and locoregional control (LRC). Also p-mTOR was histologically stained in a separate cohort of HNSCC organoids (n = 8) and correlated to mTOR-inhibitor everolimus response. RESULTS: High p-mTOR expression correlated significantly with worse OS in multivariate analysis in the whole patient cohort [Hazar Ratio (HR) 1.06, 95%CI 1.01–1.11, p = 0.03] and in the cisplatin/carboplatin group with both worse OS (HR 1.09, 95%CI 1.02–1.16, p = 0.02) and DFS (HR 1.06, 95%CI 1.00–1.12, p = 0,04). p-ERK expression correlated significantly with DFS in univariate analysis in the whole patient cohort (HR 1.03, 95%CI 1.00–1.05, p = 0.04) and cisplatin/carboplatin group (HR 1.03, 95%CI 1.00–1.07, p = 0.04). PTEN-expression did not correlate with OS/DFS/LRC. Better organoid response to everolimus correlated significantly to higher p-mTOR expression (Rs = − 0.731, p = 0.04). CONCLUSIONS: High p-mTOR expression predicts and high p-ERK expression tends to predict worse treatment outcome in HPV negative HNSCC patients treated with chemoradiation, providing additional evidence that these markers are candidate prognostic biomarkers for survival in this patient population. Also this study shows that the use of HNSCC organoids for biomarker research has potential. The role of PTEN expression as prognostic biomarker remains unclear, as consistent evidence on its prognostic and predictive value is lacking. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12105-023-01576-4. Springer US 2023-07-24 /pmc/articles/PMC10514008/ /pubmed/37486536 http://dx.doi.org/10.1007/s12105-023-01576-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
de Kort, W. W. B.
de Ruiter, E. J.
Haakma, W. E.
Driehuis, E.
Devriese, L. A.
van Es, R. J. J.
Willems, S. M.
p-mTOR, p-ERK and PTEN Expression in Tumor Biopsies and Organoids as Predictive Biomarkers for Patients with HPV Negative Head and Neck Cancer
title p-mTOR, p-ERK and PTEN Expression in Tumor Biopsies and Organoids as Predictive Biomarkers for Patients with HPV Negative Head and Neck Cancer
title_full p-mTOR, p-ERK and PTEN Expression in Tumor Biopsies and Organoids as Predictive Biomarkers for Patients with HPV Negative Head and Neck Cancer
title_fullStr p-mTOR, p-ERK and PTEN Expression in Tumor Biopsies and Organoids as Predictive Biomarkers for Patients with HPV Negative Head and Neck Cancer
title_full_unstemmed p-mTOR, p-ERK and PTEN Expression in Tumor Biopsies and Organoids as Predictive Biomarkers for Patients with HPV Negative Head and Neck Cancer
title_short p-mTOR, p-ERK and PTEN Expression in Tumor Biopsies and Organoids as Predictive Biomarkers for Patients with HPV Negative Head and Neck Cancer
title_sort p-mtor, p-erk and pten expression in tumor biopsies and organoids as predictive biomarkers for patients with hpv negative head and neck cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514008/
https://www.ncbi.nlm.nih.gov/pubmed/37486536
http://dx.doi.org/10.1007/s12105-023-01576-4
work_keys_str_mv AT dekortwwb pmtorperkandptenexpressionintumorbiopsiesandorganoidsaspredictivebiomarkersforpatientswithhpvnegativeheadandneckcancer
AT deruiterej pmtorperkandptenexpressionintumorbiopsiesandorganoidsaspredictivebiomarkersforpatientswithhpvnegativeheadandneckcancer
AT haakmawe pmtorperkandptenexpressionintumorbiopsiesandorganoidsaspredictivebiomarkersforpatientswithhpvnegativeheadandneckcancer
AT driehuise pmtorperkandptenexpressionintumorbiopsiesandorganoidsaspredictivebiomarkersforpatientswithhpvnegativeheadandneckcancer
AT devriesela pmtorperkandptenexpressionintumorbiopsiesandorganoidsaspredictivebiomarkersforpatientswithhpvnegativeheadandneckcancer
AT vanesrjj pmtorperkandptenexpressionintumorbiopsiesandorganoidsaspredictivebiomarkersforpatientswithhpvnegativeheadandneckcancer
AT willemssm pmtorperkandptenexpressionintumorbiopsiesandorganoidsaspredictivebiomarkersforpatientswithhpvnegativeheadandneckcancer